A Study of Lebrikizumab in Combination With Topical Corticosteroids in Patients With Atopic Dermatitis (AD) That Are Not Adequately Controlled With or Are Non-eligible for Cyclosporine

NCT05149313 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

331

Enrollment

INDUSTRY

Sponsor class

Conditions

Dermatitis, Atopic
Eczema

Interventions

BIOLOGICAL: Lebrikizumab
DRUG: Lebrikizumab-matching Placebo

Sponsor

Almirall, S.A.